1. Judson FN. Gonorrhae. Med Clin North Am 1990; 74; 1353.
2. Handsfield HH, Sparling PF. Neisseria gonorrhoeae. In: Mandell GL. Bennett JE, Dolin R.eds. Principles and Practice of Infectious Disease. 6th ed. New York: Churchill Livingstone; 2005:
2514.
3. https://www.who.int/news-room/fact-sheets/detail/gonorrhoea-(neisseria-gonorrhoeae-infection.
4. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to
ceftriaxone. Antimicrob Agents Chemother. 2011; 55(7): 3538–3545.
5. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;
18(3): 318–327.
6. Koneman EW, Allen SD, Janda WM, et al. Neisseria species and Mo- raxella catarrhalis. In: Diagnostic Microbiology, 5th ed New York; Lippincott Company. 1997: 491.
7. Mosleh IM, Boxberger HJ, Sessler MJ, et al. Experimental infection of native human ureteral tissue with Neisseria gonorrheae: adhesion, invasion, intracellular fate, exocytosis, and pasage
through a stratified epitelium. Infect Immun. 1997; 65: 3391.
8. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019; 97: 548-
562.
9. Unemo M, Seifert HS, Hook 3rd EW, Hawkes S, Ndowa F, Dillon JAR. Nat Rev Dis Primers. 2019; 5(1): 79.
10. Kirkcaldy RD, Weston E, Segurado AC, Hughes G. Epidemiology of gonorrhea: a global perspective. Sex Health. 2019; 16(5): 401-411.
11. Hedges SR, Mayo MS, Mestecky J, et al. Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun. 1999; 67: 3937.
12. Töreci K, Sabri MA. Penisilinaz meydana getiren Neisseria gonorrhoeae suşu. Ankem Derg. 1987; 3: 247.
13. Koksal I, Ozgur G, Piskin B. Penicillinase producing Neisseria go- norrhoeae strains in East Black Sea Region of Turkey. Infection. 1990; 18: 396.
14. Aydın M.D. Neisseria gonorrhoeae suşlarında antibiyotik direnci ve beta-laktamaz üretimi: 1996-2001. ANKEM Derg. 2002; 16(4): 481-485 .
15. Zenilman JM, Nims LJ, Menegus MA, el al. Spectinomycin resistant gonococcal infections in the United States. J Infect Dis. 1987; 156: 1002.
16. Fox KK, Knapp JS, Holmes KK. Antimicrobial resistance in Neisseria gonorrhoae in the United States 1998-1994. Emergence of resistance to the fluoroquinolones. J Infect Dis. 1997; 175: 1396.
17. Zenilman JA. Update on quinolone-resistance in Neisseria gonorrhoae. Curr Infect Dis Rep. 2002; 4: 144.
18. Aplasca de los reyes MR, Pato-Mesola V. Klausner JD. A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resis-
tance in Philipines. Clin Infect Dis. 2001; 32: 1313.
19. Unemo M, Lahra MM, Escher M, et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study. Lancet Microbe. 2021; 2(11):
e627-e636.
20. Quillin SJ, Seifert HS. Neisseria gonorrhoeae host-adaptation and pathogenesis. Nat Rev Microbiol. 2018; 16(4): 226-240.
21. Liu Y, Islam E, Jarvis G, Gray-Owen S, Russell M. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-α
dependent mechanisms. Mucosal Immunol. 2012; 5(3): 320-31.
22. Liu Y, Liu W, Russell MW. Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells. Mucosal Immunol. 2014; 7(1):
165–176.
23. Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic as- pects. Genitourin Med 1996; 72: 422.
24. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2021. MMWR Recomm Rep. 2021; 70(4): 1-187.
25. Barlow D, Phillips I. Gonorrhoeae in women: diagnostic, clinical and laboratory aspects. Lancet 1978; I: 761.
26. Klein EJ, Fisher LS, Chow AW, Guze LB. Anorectal gonococcal infection. Ann Intern Med. 1977; 86: 340.
27. Kraus SJ. Incidence and therapy of gonococcal pharyngitis. Sex Transm Dis. 1979; 6: 143.
28. Weström L, Eschenbach D. Pelvic inflammatory disease. In: Holmes KK, Sparling PF, Märdh PA, et al. ed. Sexually transmitted diseases, New York: McGraw-Hill; 1999: 783-809.
29. Paul Nyirjesy P, Dallabetta G. Pelvic Inflammatory Disease. In: Co- hen J, Powderly WG, Opal SM. Infectious Disease. 3th ed. Mosby El- sevier. 2010; 551 – 553.
30. Ertunç B, Yılmaz G. Pelvik Enflamatuvar Hastalık. Editörler: Kurt H, Gündeş S, Geyik MF. Enfeksiyon Hastalıkları. Nobel tıp kitabevleri. 2013; 355-357.
31. Jephcott AE. Microbiological diagnosis of gonorrhoeae. Genitourin Med. 1997; 73: 245.
32. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP
Malawi Research Group. Lancet. 1997; 349: 1868.
33. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin
Infect Dis. 2014; 59: 1083–91.
34. Ross JDC, Brittain C, Cole M, et al.; G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet. 2019; 393:
2511–20.
35. Berenger BM, Demczuk W, Gratrix J, Pabbaraju K, Smyczek P, Martin I. Genetic characterization and enhanced surveillance of ceftriaxone-resistant Neisseria gonorrhoeae strain, Alberta,
Canada, 2018. Emerg Infect Dis. 2019; 25: 1660–7.
36. Bleich AT, Sheffield JS, Wendel GD Jr, Sigman A, Cunningham FG. Disseminated gonococcal infection in women. Obstet Gynecol. 2012; 119: 597 – 602.
37. Birrell JM, Gunathilake M, Singleton S, Williams S, Krause V. Characteristics and impact of disseminated gonococcal infection in the “Top End” of Australia. Am J Trop Med Hyg. 2019; 101:
753–760.
38. Crew PE, Abara WE, McCulley L, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis. 2019; 69: 596–600.
39. Rietmeijer CA, Mungati M, Machiha A, et al. The etiology of male urethral discharge in Zimbabwe: results from the Zimbabwe STI Etiology Study. Sex Transm Dis. 2018; 45: 56–60.
40. Frølund M, Lidbrink P, Wikström A, Cowan S, Ahrens P, Jensen J. Urethritis-associated pathogens in urine from men with non-gonococcal urethritis: a case-control study. Acta Derm Vene-
reol. 2016; 96: 689–94.
41. Chambers LC, Morgan JL, Lowens MS, et al. Cross-sectional study of urethral exposures at last sexual episode associated with non-gonococcal urethritis among STD clinic patients. Sex
Transm Infect. 2019; 95: 212–218.
42. Manhart LE, Khosropour CM, Liu C, et al. Bacterial vaginosisassociated bacteria in men: association of Leptotrichia/Sneathia spp. with nongonococcal urethritis. Sex Transm Dis. 2013; 40:
944–949.
43. Young A, Toncar A, Wray A. Urethritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.2022 Dec 1.
44. Territo H, Ashurst JV. Nongonococcal Urethritis. 2023; In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.2023 Aug 14.
45. Bachmann LH, Kirkcaldy RD, Geisler WM, et al.; the MAGNUM Laboratory Working Group. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symp-
tom resolution following treatment of urethritis. Clin Infect Dis. 2020; 71: e624–632.
46. Sell J, Nasir M, Courchesne C. Urethritis: Rapid Evidence Review. Am Fam Physician. 2021; 103(9): 553-558.
47. Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV infected men who have sex with men who continue
to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015; 42: 98–103.
48. Régnier SA, Huels J. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. Hum Vaccin Immu-
nother. 2014; 10: 3737–3745.
49. Whittles LK, Didelot X, White PJ. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis. Lancet
Infect Dis. 2022; 22: 1030–1041.
50. Heijne JCM, Xiridou M, Turner KME, et al. The impact of vaccination on Neisseria gonorrhoeae antimicrobial resistance and prevalence in men who have sex with men: a mathematical
modelling study. 2020; medRxiv.